GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Institutional Ownership

Cyclacel Pharmaceuticals (STU:UXI) Institutional Ownership : 0.52% (As of Jun. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cyclacel Pharmaceuticals's institutional ownership is 0.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cyclacel Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cyclacel Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 94.52%.


Cyclacel Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Institutional Ownership Chart

Cyclacel Pharmaceuticals Historical Data

The historical data trend for Cyclacel Pharmaceuticals can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 1.26 0.95 0.95 0.95 0.73 0.73 0.58 0.58 0.58 0.52

Cyclacel Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cyclacel Pharmaceuticals (STU:UXI) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines